NasdaqGS:AXGT

Stock Analysis Report

Executive Summary

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases.

Snowflake

Fundamentals

Moderate growth potential with imperfect balance sheet.

Risks

  • Axovant Gene Therapies has significant price volatility in the past 3 months.

Share Price & News

How has Axovant Gene Therapies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.6%

NasdaqGS:AXGT

-2.7%

US Biotechs

-1.9%

US Market


1 Year Return

-64.3%

NasdaqGS:AXGT

-11.8%

US Biotechs

-3.3%

US Market

AXGT underperformed the Biotechs industry which returned -11.5% over the past year.

AXGT underperformed the Market in United States of America which returned -3% over the past year.


Share holder returns

AXGTIndustryMarket
7 Day-4.6%-2.7%-1.9%
30 Day-2.3%-1.5%-6.2%
90 Day-8.7%0.08%0.3%
1 Year-64.3%-64.3%-11.1%-11.8%-1.1%-3.3%
3 Year-95.2%-95.2%8.7%4.9%37.9%28.9%
5 Yearn/a1.9%-2.8%50.8%34.1%

Price Volatility Vs. Market

How volatile is Axovant Gene Therapies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Axovant Gene Therapies undervalued based on future cash flows and its price relative to the stock market?

4.98x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Axovant Gene Therapies to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Axovant Gene Therapies to establish if it is available at substantial discount.


Price Based on Earnings

Axovant Gene Therapies is loss making, we can't compare its value to the US Biotechs industry average.

Axovant Gene Therapies is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Axovant Gene Therapies, we can't assess if its growth is good value.


Price Based on Value of Assets

Axovant Gene Therapies is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Axovant Gene Therapies expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

56.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Axovant Gene Therapies is high growth as no revenue estimate data is available.

Axovant Gene Therapies's earnings are expected to grow significantly at over 20% yearly.

Unable to compare Axovant Gene Therapies's revenue growth to the United States of America market average as no estimate data is available.

Axovant Gene Therapies's earnings growth is expected to exceed the United States of America market average.

Axovant Gene Therapies's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Axovant Gene Therapies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Axovant Gene Therapies performed over the past 5 years?

-6.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Axovant Gene Therapies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Axovant Gene Therapies's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Axovant Gene Therapies's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Axovant Gene Therapies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Axovant Gene Therapies has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Axovant Gene Therapies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Axovant Gene Therapies's financial position?


Financial Position Analysis

Axovant Gene Therapies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Axovant Gene Therapies's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Axovant Gene Therapies's level of debt (134.2%) compared to net worth is high (greater than 40%).

Unable to establish if Axovant Gene Therapies's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Axovant Gene Therapies has less than a year of cash runway based on current free cash flow.

Axovant Gene Therapies has less than a year of cash runway if free cash flow continues to grow at historical rates of 14.1% each year.


Next Steps

Dividend

What is Axovant Gene Therapies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Axovant Gene Therapies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Axovant Gene Therapies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Axovant Gene Therapies has not reported any payouts.

Unable to verify if Axovant Gene Therapies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Axovant Gene Therapies has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Axovant Gene Therapies's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average management tenure


CEO

Pavan Cheruvu (37yo)

1.5yrs

Tenure

US$1,028,744

Compensation

Dr. Pavan Cheruvu, M.D., has been Chief Executive Officer of Axovant Sciences Ltd. since February 12, 2018 and as its Director since September 26, 2018. Dr. Cheruvu provides medical oversight for Hale’s wo ...


CEO Compensation Analysis

Pavan's remuneration is higher than average for companies of similar size in United States of America.

Insufficient data for Pavan to compare compensation growth.


Management Age and Tenure

1.5yrs

Average Tenure

53.5yo

Average Age

The average tenure for the Axovant Gene Therapies management team is less than 2 years, this suggests a new team.


Board Age and Tenure

0.9yrs

Average Tenure

60yo

Average Age

The average tenure for the Axovant Gene Therapies board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by Axovant Gene Therapies individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$39,07517 Jun 19
Pavan Cheruvu
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares7,500
Max PriceUS$5.21
BuyUS$17,59517 Jun 19
Atul Pande
EntityIndividual
Role
Lead Director
Lead Independent Director
Shares3,370
Max PriceUS$5.22
BuyUS$10,000,00119 Mar 19
Roivant Sciences Ltd.
EntityCompany
Shares833,333.38
Max PriceUS$12.00
BuyUS$10,000,00020 Dec 18
Roivant Sciences Ltd.
EntityCompany
Shares1,250,000
Max PriceUS$8.00

Ownership Breakdown


Management Team

  • David Hung (61yo)

    Scientific Advisor of Group

    • Tenure: 1.5yrs
    • Compensation: US$54.28m
  • David Nassif (65yo)

    CFO & Principal Accounting Officer

    • Tenure: 0.1yrs
  • Gavin Corcoran (56yo)

    Chief R&D Officer of Axovant Sciences

    • Tenure: 1.1yrs
    • Compensation: US$1.37m
  • Ilise Lombardo

    Chief Medical Officer

    • Tenure: 4.3yrs
  • Marianne Dinsmore (51yo)

    Head of Global Transactions & Risk Management

    • Tenure: 4.4yrs
    • Compensation: US$1.07m
  • Pavan Cheruvu (37yo)

    CEO & Director

    • Tenure: 1.5yrs
    • Compensation: US$1.03m
  • Shankar Ramaswamy

    Chief Business Officer

    • Tenure: 1.5yrs
  • Fraser Wright

    Chief Technology Officer

    • Tenure: 1.6yrs
  • Tricia Truehart

    Head of Investor Relations

    • Tenure: 0.0yrs
  • Mat Bazley (46yo)

    General Counsel

    • Tenure: 0.8yrs
    • Compensation: US$1.15m

Board Members

  • Myrtle Potter (61yo)

    Director

    • Tenure: 0.9yrs
    • Compensation: US$274.08k
  • Michael Hayden (68yo)

    Senior Scientific Advisor & Chairman of the Scientific Advisory Board

    • Tenure: 1.3yrs
  • George Bickerstaff (63yo)

    Director

    • Tenure: 1.5yrs
    • Compensation: US$57.75k
  • Berndt A. Modig (60yo)

    Director

    • Tenure: 4.4yrs
    • Compensation: US$63.25k
  • Atul Pande (64yo)

    Lead Independent Director

    • Tenure: 0.9yrs
    • Compensation: US$71.50k
  • Frank Torti (40yo)

    Chairperson

    • Tenure: 0.9yrs
    • Compensation: US$282.00k
  • Ilan Oren (35yo)

    Director

    • Tenure: 1.2yrs
  • Pavan Cheruvu (37yo)

    CEO & Director

    • Tenure: 1.5yrs
    • Compensation: US$1.03m
  • Senthil Sundaram (41yo)

    Director

    • Tenure: 0.1yrs

Company Information

Axovant Gene Therapies Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Axovant Gene Therapies Ltd.
  • Ticker: AXGT
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$146.252m
  • Shares outstanding: 22.78m
  • Website: https://www.axovant.com

Number of Employees


Location

  • Axovant Gene Therapies Ltd.
  • 11-12 St. James's Square
  • 3rd Floor
  • London
  • Greater London
  • SW1Y 4LB
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AXGTNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJun 2015
3ASAMUN (Boerse Muenchen)YesCommon SharesDEEURJun 2015
3ASADB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2015

Biography

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company’s current pi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/26 01:16
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.